Applied UV Leverages World Cannabis Day 4:20

Applied UV Leverages World Cannabis Day 4:20

Launches New Website and Marketing Campaign

Applied UV, Inc. (NasdaqCM: AUVI ) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced, that in recognizing the business significance of the historic 4:20 World Cannabis Day, its wholly owned subsidiary Sterilumen launched an integrated, multi-touchpoint marketing campaign targeting the $20B North American Cannabis Market.

The Company has also forged a strategic multi-media-platform partnership with Cannabis Business Times to educate growers and operations leaders the criticality of pure, high-quality air in the grow environment. The campaign includes the redesigned and launch of the Airoclean420 website, as well as leads-generation ads on several platforms and advertising across print, e-Newsletter, and digital video and print platforms. In addition, the Company plans to exhibit its Airoclean™ 420 by Sterilumen at the Cannabis Business Times' Cannabis Conference in Las Vegas August 23-25, 2022. The Cannabis marketing initiative marks the first of many planned investments into our three acquired Companies (Akida Holdings, Kes Science and Scientific Air Management) targeting key verticals of growth that we expect to increase brand recognition, drive both market share and top line revenue.

John F. Andrews, Applied UV's Chief Executive Officer commented, "We are proactively pursuing the high growth cannabis market with the launch of this multi-faceted marketing program. Healthy air is an essential element in growing cannabis and can determine whether the yield produced will be a bumper crop or a total flop. Our Airoclean™ 420 by Sterilumen, dramatically improves crop yield by purifying the air in the growing environment by trapping and destroying all airborne powdery mildew and other fungal diseases. We believe there is tremendous opportunity for our solutions to improve the operations of cannabis growers. We are getting this message out to the industry through the launch of the airoclean420 website and other related marketing initiatives."

Airoclean™ 420 by Sterilumen launched in 2015 is a pioneering brand that has been trusted for more than a decade by commercial and home/hobby growers across North America and, is the most effective air purification system in destroying powdery mildew and airborne fungal diseases that ruin cannabis plants and businesses. The cannabis crop is subject to many viruses that could impede growth and destroy crops. Powdery mildew is one of the most potent destroyers of cannabis grows in the world. The pathogen spreads through the air and gets into the vascular system of the plants. It remains hidden until two weeks into flowering before it wreaks havoc on the entire grow. When it is detected, growers must destroy the crop, remove all their equipment, and conduct an intensive and costly deep clean. Certain fungicides can combat powdery mildew, but these are illegal in some states and are of questionable safety given they are sprayed on something intended for human consumption. Airoclean™ 420 by Sterilumen eradicates powdery mildew and other airborne pathogens and not only protects the crops but helps protect the personnel from airborne pathogens working in the facilities growing them as well.

For additional information about the Company's Cannabis products, please visit https://www.airoclean420.com/ .

About Applied UV

Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen's connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company's Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices' proximity. The Company's patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen's Airocide® air purification devices are research backed, clinically proven, and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photocatalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities and homes. For more information about Applied UV, Inc., and its subsidiaries, please visit the following website: https://www.applieduvinc.com/ ;

Forward-Looking Statements

The information contained herein may contain "forward‐looking statements." Forward‐looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.

For additional Company Information:

Applied UV Inc.
John F. Andrews
CEO/Director
john.andrews@applieduvinc.com

Brett Maas, Managing Principal
Hayden IR
brett@haydenir.com
(646) 536-7331

News Provided by Business Wire via QuoteMedia

AUVI:NSD
The Conversation (0)

Medtronic reports third quarter fiscal 2024 financial results

Delivers on commitments with strong growth in Core Spine, Cardiac Surgery, Structural Heart, Cardiac Pacing, and across many international markets; Diabetes increases double digits as U.S. business returns to growth; Raises full year guidance

Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2024 (FY24), which ended January 26, 2024 .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Medical Technology Stocks to Keep On The Radar

(NewsDirect)

The healthcare technology industry is one that offers investors a plethora of opportunities. With global healthcare spending soaring to approximately $8.3 trillion and nearly half of that amount allocated in the U.S. alone, the sector presents intriguing growth prospects. As the healthcare industry outpaces the overall global economy in growth, investors find themselves on the cusp of a promising market.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

Making Earlier Detection of Ovarian Cancer a Reality

Corporate Presentation February 2024

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is bringing to market a simple blood test for the accurate and early diagnosis of ovarian cancer, using its novel patented CXCL10 biomarker.

Keep reading...Show less
cardiologist wearing virtual reality glasses

2 Biggest Medical Device ETFs in 2024

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less

Salix Announces 2024 Gastrointestinal Health Scholars Program

Salix to Provide Scholarships to 10 Students Living with GI Diseases

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the opening of the 2024 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 exceptional students living with GI disease a scholarship of up to $10,000 as they work to pursue their higher education goals

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

Cleo Completes Design Transfer

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to confirm that it has concluded design transfer activities relating to the core technology for its ovarian cancer detection test.

Keep reading...Show less

Latest Press Releases

Related News

×